Shareholders back AN2 Therapeutics (NASDAQ: ANTX) directors and auditor
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
AN2 Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders. A quorum was present, with 22,741,535 shares represented, equal to 63.18% of the 35,995,545 shares outstanding as of April 15, 2026.
Stockholders elected Class I directors Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D., to serve until the 2029 annual meeting or until their successors are chosen. Support ranged from 13,547,536 to 15,947,854 votes for, with broker non-votes of 5,235,125 on each nominee.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 22,724,674 votes for, 13 votes against, and 16,848 abstentions.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares represented: 22,741,535 shares
Shares outstanding: 35,995,545 shares
Quorum percentage: 63.18%
+4 more
7 metrics
Shares represented
22,741,535 shares
Present at 2026 annual meeting
Shares outstanding
35,995,545 shares
Common stock outstanding as of April 15, 2026
Quorum percentage
63.18%
Portion of outstanding shares represented at meeting
Votes for Aziz
13,547,536 votes
Election of director Kabeer Aziz
Votes for Marks
15,947,854 votes
Election of director Gilbert Lynn Marks, M.D.
Votes for Readnour
15,920,563 votes
Election of director Rob Readnour, Ph.D.
Auditor ratification for votes
22,724,674 votes
Ratification of PricewaterhouseCoopers LLP
Key Terms
broker non-votes, independent registered public accounting firm, emerging growth company, record date
4 terms
broker non-votes financial
"including the number of votes cast for or against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
record date financial
"outstanding as of the close of business on April 15, 2026, the record date for the Annual Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
FAQ
What did AN2 Therapeutics (ANTX) report from its 2026 annual meeting?
AN2 Therapeutics reported the voting results from its 2026 annual meeting. Shareholders elected three Class I directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Which directors were elected at the AN2 Therapeutics (ANTX) 2026 annual meeting?
Stockholders elected Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D., as Class I directors. They will serve until the 2029 annual meeting of stockholders or until their respective successors are elected or appointed, according to the reported vote results.
What were the vote totals for AN2 Therapeutics (ANTX) auditor ratification?
Shareholders ratified PricewaterhouseCoopers LLP as AN2 Therapeutics’ independent registered public accounting firm. The proposal received 22,724,674 votes for, 13 votes against, and 16,848 abstentions for the fiscal year ending December 31, 2026.
What was the record date for AN2 Therapeutics (ANTX) 2026 annual meeting voting eligibility?
The record date for determining shareholders entitled to vote at AN2 Therapeutics’ 2026 annual meeting was April 15, 2026. On that date, 35,995,545 shares of common stock were outstanding and eligible to be counted for quorum and voting purposes.